In a medical breakthrough that offers new
hope to people with spinal cord injuries,
scientists have used a brain implant to
enable partially paralyzed monkeys to
regain the ability to walk. Researchers at
the Swiss Federal Institute of Technology
implanted the device in the monkey’s
motor cortex, or movement center, where
it recorded neural activity. This data was
then wirelessly routed to a second implant
placed on the spinal
cord beyond
the injured nerves,
which triggered the
intended movements.
Two monkeys
fitted with this
“brain-spine
interface” system
regained the ability to walk within days,
and were fully mobile after three months.
“It was a big surprise for us,” Grégoire
Courtine, a neuroscientist who led the
research, tells The Guardian (U.K.). “The
gait was not perfect, but it was almost like
normal walking. The foot was not dragging
and it was fully weight-bearing.” The
implant’s components—which took seven
years to develop, after 10 years of work on
rodents—are already approved for use in
humans. But helping monkeys walk using
four limbs is much less challenging than
enabling paralyzed people to balance and
walk on two legs. Nevertheless, researchers
believe the technology could be transferred
to humans within a decade.
homeowners insurance Claim
home insurance Claim
state farm car insurance Claim
comprehensive insurance Claim
commercial insurance Claim
cheap auto insurance Claim
cheap health insurance Claim
indemnity Claim
car insurance companies Claim
progressive quote Claim
usaa car insurance Claim
insurance near me Claim
term life insurance Claim
auto insurance near me Claim
state farm car insurance Claim
comprehensive insurance Claim
progressive home insurance Claim
house insurance Claim
progressive renters insurance Claim
state farm insurance quote Claim
metlife auto insurance Claim
best insurance companies Claim
progressive auto insurance quote Claim
cheap car insurance quotes Claim
allstate car insurance Claim
rental car insurance Claim
car insurance online Claim
liberty mutual car insurance Claim
cheap car insurance near me Claim
best auto insurance Claim
home insurance companies Claim
usaa home insurance Claim
list of car insurance companies Claim
full coverage insurance Claim
allstate insurance near me Claim
cheap insurance quotes Claim
national insurance Claim
progressive home insurance Claim
house insurance Claim
health insurance quotes Claim
ameritas dental Claim
state farm renters insurance Claim
medicare supplement plans Claim
progressive renters insurance Claim
aetna providers Claim
title insurance Claim
sr22 insurance Claim
medicare advantage plans Claim
aetna health insurance Claim
ambetter insurance Claim
umr insurance Claim
massmutual 401k Claim
private health insurance Claim
assurant renters insurance Claim
assurant insurance Claim
dental insurance plans Claim
state farm insurance quote Claim
health insurance plans Claim
workers compensation insurance Claim
geha dental Claim
metlife auto insurance Claim
boat insurance Claim
aarp insurance Claim
costco insurance Claim
flood insurance Claim
best insurance companies Claim
cheap car insurance quotes Claim
best travel insurance Claim
insurance agents near me Claim
car insurance Claim
car insurance quotes Claim
auto insurance Claim
auto insurance quotes Claim
long term care insurance Claim
auto insurance companies Claim
home insurance quotes Claim
cheap car insurance quotes Claim
affordable car insurance Claim
professional liability insurance Claim
cheap car insurance near me Claim
small business insurance Claim
vehicle insurance Claim
best auto insurance Claim
full coverage insurance Claim
motorcycle insurance quote Claim
homeowners insurance quote Claim
errors and omissions insurance Claim
general liability insurance Claim
best renters insurance Claim
cheap home insurance Claim
cheap insurance near me Claim
cheap full coverage insurance Claim
cheap life insurance Claim
Supercharging statins
Statins have become the “gold standard”
for the treatment of high cholesterol—and
a new type of drug known as PCSK9
inhibitors could make them even better. In
a recent study, researchers split a group of
968 volunteers into two groups: one tak
Statins have become the “gold standard”
for the treatment of high cholesterol—and
a new type of drug known as PCSK9
inhibitors could make them even better. In
a recent study, researchers split a group of
968 volunteers into two groups: one taking
only a statin, the other combining the
drug with evolocumab, a PCSK9 inhibitor.
After 18 months, the team measured
the participants’ levels of LDL, or “bad
cholesterol.” Anything below 100 milligrams
per deciliter of blood is considered
excellent, and those who were taking only
a statin averaged an impressive 93 mg/dL.
But those taking a combination of the two
drugs averaged an astonishing 36 mg/dL
of LDL—an ultralow level generally seen
only in babies. “In a sense,” says cardiologist
Elliott Antman, who wasn’t associated
with the study, “you are turning back
the cardiovascular clock.” These striking
reductions came with an added benefit,
reports Reuters.com: greater declines in
dangerous plaques that had accumulated
in the patients’ arteries. Plaques shrank in
two-thirds of those taking both drugs, but
in only half of those taking a statin alone.
The only downside of PCSK9 inhibitors is
their cost: With some prescriptions priced
at $14,000 a year, most insurers are refusing
to pay for them.
for the treatment of high cholesterol—and
a new type of drug known as PCSK9
inhibitors could make them even better. In
a recent study, researchers split a group of
968 volunteers into two groups: one tak
Statins have become the “gold standard”
for the treatment of high cholesterol—and
a new type of drug known as PCSK9
inhibitors could make them even better. In
a recent study, researchers split a group of
968 volunteers into two groups: one taking
only a statin, the other combining the
drug with evolocumab, a PCSK9 inhibitor.
After 18 months, the team measured
the participants’ levels of LDL, or “bad
cholesterol.” Anything below 100 milligrams
per deciliter of blood is considered
excellent, and those who were taking only
a statin averaged an impressive 93 mg/dL.
But those taking a combination of the two
drugs averaged an astonishing 36 mg/dL
of LDL—an ultralow level generally seen
only in babies. “In a sense,” says cardiologist
Elliott Antman, who wasn’t associated
with the study, “you are turning back
the cardiovascular clock.” These striking
reductions came with an added benefit,
reports Reuters.com: greater declines in
dangerous plaques that had accumulated
in the patients’ arteries. Plaques shrank in
two-thirds of those taking both drugs, but
in only half of those taking a statin alone.
The only downside of PCSK9 inhibitors is
their cost: With some prescriptions priced
at $14,000 a year, most insurers are refusing
to pay for them.
Subscribe to:
Posts (Atom)